Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Previously Treated Malignant Mesothelioma
NCT00137826Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in malignant mesothelioma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 3 years. Started Feb 2004; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00137826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137826.